HK1209275A1 - Non human animals having a humanized signal regulatory protein gene - Google Patents

Non human animals having a humanized signal regulatory protein gene

Info

Publication number
HK1209275A1
HK1209275A1 HK15109933.4A HK15109933A HK1209275A1 HK 1209275 A1 HK1209275 A1 HK 1209275A1 HK 15109933 A HK15109933 A HK 15109933A HK 1209275 A1 HK1209275 A1 HK 1209275A1
Authority
HK
Hong Kong
Prior art keywords
protein gene
human animals
regulatory protein
non human
signal regulatory
Prior art date
Application number
HK15109933.4A
Other languages
English (en)
Chinese (zh)
Inventor
Andrew J Murphy
O Gavin Thurston
Bindu Varghese
Cagan Gurer
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HK1209275A1 publication Critical patent/HK1209275A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C12N2015/8572—Animal models for proliferative diseases, e.g. comprising an oncogene
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
HK15109933.4A 2013-09-23 2015-10-12 Non human animals having a humanized signal regulatory protein gene HK1209275A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361881261P 2013-09-23 2013-09-23
PCT/US2014/056910 WO2015042557A1 (fr) 2013-09-23 2014-09-23 Animaux non humains possédant un gène humanisé de la protéine régulatrice du signal

Publications (1)

Publication Number Publication Date
HK1209275A1 true HK1209275A1 (en) 2016-04-01

Family

ID=51663510

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109933.4A HK1209275A1 (en) 2013-09-23 2015-10-12 Non human animals having a humanized signal regulatory protein gene

Country Status (28)

Country Link
US (9) US9193977B2 (fr)
EP (4) EP3434101B1 (fr)
JP (4) JP6453893B2 (fr)
KR (2) KR102407354B1 (fr)
CN (2) CN108441497B (fr)
AU (1) AU2014321187B2 (fr)
CA (1) CA2925564C (fr)
CY (1) CY1121410T1 (fr)
DK (3) DK2922394T3 (fr)
ES (3) ES2710282T3 (fr)
FI (1) FI3434101T3 (fr)
HK (1) HK1209275A1 (fr)
HR (2) HRP20231121T1 (fr)
HU (2) HUE042412T2 (fr)
IL (4) IL297607B2 (fr)
LT (2) LT3175706T (fr)
MX (1) MX368931B (fr)
NZ (1) NZ717817A (fr)
PH (1) PH12016500342A1 (fr)
PL (2) PL3434101T3 (fr)
PT (3) PT3434101T (fr)
RS (2) RS64573B1 (fr)
RU (2) RU2671166C2 (fr)
SG (3) SG11201601184UA (fr)
SI (2) SI3434101T1 (fr)
TR (1) TR201901782T4 (fr)
WO (1) WO2015042557A1 (fr)
ZA (1) ZA201601138B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2908587T3 (es) 2009-10-06 2022-05-03 Regeneron Pharma Ratones modificados genéticamente e injerto
DK3375284T3 (da) 2011-02-15 2023-06-12 Univ Yale Humaniserede M-CSF-mus og anvendelser deraf
EP4193834A1 (fr) 2012-09-07 2023-06-14 Yale University Animaux non humains génétiquement modifiés et leurs procédés d'utilisation
EP3556206B1 (fr) 2012-11-05 2021-06-02 Regeneron Pharmaceuticals, Inc. Rongeurs génétiquement modifiés et leurs procédés d'utilisation
RS64573B1 (sr) * 2013-09-23 2023-10-31 Regeneron Pharma Ne-humana životinja sa humanizovanim signalno-regulatornim proteinskim genom
SI3138397T1 (sl) 2013-10-15 2019-04-30 Regeneron Pharmaceuticals, Inc. Humanizirane živali IL-15
ES2794942T3 (es) 2014-04-08 2020-11-19 Regeneron Pharma Animales no humanos que tienen receptores Fc-gamma humanizados
NO2785538T3 (fr) 2014-05-07 2018-08-04
DK3841877T3 (da) 2014-05-19 2023-11-27 Regeneron Pharma Genetisk modificeret mus, der eksprimerer human EPO
RU2735958C2 (ru) 2014-06-19 2020-11-11 Регенерон Фармасьютикалз, Инк. Животные, отличные от человека, имеющие гуманизированный ген 1 запрограммированной гибели клеток
RU2020122439A (ru) 2014-11-24 2020-09-24 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3
US20160345549A1 (en) 2014-12-05 2016-12-01 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 47 gene
JP6752221B2 (ja) * 2015-04-13 2020-09-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｓｉｒｐａ−ｉｌ１５ノックインマウス及びその使用方法
CN104904661B (zh) * 2015-06-05 2018-07-24 杭州正因生物技术有限公司 一种人源化小鼠
SG10201912905VA (en) 2015-08-07 2020-02-27 Alx Oncology Inc Constructs having a sirp-alpha domain or variant thereof
KR102454546B1 (ko) 2015-11-20 2022-10-14 리제너론 파마슈티칼스 인코포레이티드 인간화 림프구 활성화 유전자 3을 갖는 비인간 동물
KR102487839B1 (ko) 2016-02-04 2023-01-12 리제너론 파마슈티칼스 인코포레이티드 조작된 angptl8 유전자를 갖는 비인간 동물
KR102493894B1 (ko) 2016-02-29 2023-01-31 리제너론 파마슈티칼스 인코포레이티드 인간화 tmprss 유전자를 갖는 설치류
CN108588126B (zh) 2017-03-31 2020-04-10 北京百奥赛图基因生物技术有限公司 Cd47基因人源化改造动物模型的制备方法及应用
WO2018177441A1 (fr) * 2017-03-31 2018-10-04 Beijing Biocytogen Co., Ltd ANIMAL NON HUMAIN GÉNÉTIQUEMENT MODIFIÉ COMPRENANT UN SIRPα HUMAIN OU CHIMÉRIQUE
WO2018233608A1 (fr) * 2017-06-19 2018-12-27 Beijing Biocytogen Co., Ltd Animal non humain génétiquement modifié à cd28 humaine ou chimérique
CN109136261B (zh) 2017-06-19 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化cd28基因改造动物模型的制备方法及应用
AU2018309716A1 (en) 2017-07-31 2020-01-16 Regeneron Pharmaceuticals, Inc. Cas-transgenic mouse embryonic stem cells and mice and uses thereof
CN111182790A (zh) 2017-07-31 2020-05-19 瑞泽恩制药公司 Crispr报告体非人类动物及其用途
EP4276185A3 (fr) * 2017-09-29 2024-02-21 Regeneron Pharmaceuticals, Inc. Rongeurs comprenant un locus ttr humanisé et procédés d'utilisation
CN116064611A (zh) 2017-11-30 2023-05-05 瑞泽恩制药公司 包含人源化trkb基因座的非人动物
CA3089331A1 (fr) 2018-03-19 2019-09-26 Regeneron Pharmaceuticals, Inc. Modulation de la transcription chez des animaux a l'aide de systemes crispr/cas
CA3093850A1 (fr) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Rongeurs humanises pour tester des agents therapeutiques
CN116200426A (zh) 2018-07-16 2023-06-02 瑞泽恩制药公司 Ditra疾病的非人动物模型及其用途
US20220120731A1 (en) * 2019-02-01 2022-04-21 The Board Of Trustees Of The Leland Stanford Junior University SIRPa EXPRESSION ON T CELLS IS A BIOMARKER FOR FUNCTIONAL T CELLS DURING EXHAUSTION
IL286905B1 (en) 2019-04-04 2024-02-01 Regeneron Pharma Non-human animals containing the human coagulation factor 12 locus
MX2021014627A (es) 2019-05-31 2022-01-06 Alx Oncology Inc Polipeptidos de citocinas enmascaradas.
EP3801011A1 (fr) 2019-06-04 2021-04-14 Regeneron Pharmaceuticals, Inc. Animaux non humains comprenant un locus ttr humanisé ayant une mutation bêta-slip et procédés d'utilisation
KR20220017939A (ko) 2019-06-07 2022-02-14 리제너론 파마슈티칼스 인코포레이티드 인간화 알부민 좌위를 포함하는 비-인간 동물
US20230058049A1 (en) * 2019-12-31 2023-02-23 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED IMMUNODEFICIENT NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPa/CD47
EP4138550A1 (fr) 2020-04-21 2023-03-01 Regeneron Pharmaceuticals, Inc. Animaux non humains ayant un gène cxcl13 humanisé
IL303724A (en) 2020-12-21 2023-08-01 Regeneron Pharma Non-human animals with a humanized TSLP gene, a humanized TSLP receptor gene, and/or a humanized IL7RA gene
WO2023143341A1 (fr) * 2022-01-25 2023-08-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Animal non humain génétiquement modifié porteur d'un nkp46 humain ou chimérique
WO2024020057A1 (fr) 2022-07-19 2024-01-25 Regeneron Pharmaceuticals, Inc. Modèle animal génétiquement modifié et son utilisation pour modéliser le système immunitaire humain
US20240130341A1 (en) 2022-09-29 2024-04-25 Regeneron Pharmaceuticals, Inc. Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149635A (en) * 1986-09-12 1992-09-22 Abbott Biotech, Inc. Messenger RNA stabilization in animal cells
EP1027431A2 (fr) 1997-09-12 2000-08-16 Apotech R&D S.A. Nouveaux ligands de la famille des tnf
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ATE510020T1 (de) * 2003-12-24 2011-06-15 G2 Inflammation Pty Ltd Transgenes nichtmenschliches säugetier mit einem polynukleotid, das für human-c5ar oder humanisiertes c5ar codiert
ES2667169T3 (es) 2004-10-19 2018-05-09 Regeneron Pharmaceuticals, Inc. Método para generar un animal no humano homocigótico para una modificación genética
US20060272038A1 (en) * 2005-05-27 2006-11-30 Michael De Vivo Transgenic Alzheimer's mouse model vectors and uses thereof
US20070028316A1 (en) * 2005-06-02 2007-02-01 Xiaoxia Li Transgenic non-human Act1-deficient mammals and uses thereof
WO2009046541A1 (fr) * 2007-10-11 2009-04-16 University Health Network Modulation de l'interaction sirpα - cd47 pour augmenter la prise de greffe des cellules souches hématopoïétiques humaines et leurs composés
TWI476280B (zh) 2008-03-07 2015-03-11 Regeneron Pharma 來自二倍體宿主胚胎注射之ｅｓ－細胞衍生的老鼠
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
ES2908587T3 (es) 2009-10-06 2022-05-03 Regeneron Pharma Ratones modificados genéticamente e injerto
WO2012040207A2 (fr) 2010-09-20 2012-03-29 Yale University Animaux transgéniques à sirpaα humain et leurs procédés d'utilisation
NZ759163A (en) * 2011-02-14 2023-03-31 Revivicor Inc Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
DK3375284T3 (da) 2011-02-15 2023-06-12 Univ Yale Humaniserede M-CSF-mus og anvendelser deraf
SI2770821T1 (en) 2011-10-28 2018-01-31 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex of mice
SG10201600965YA (en) 2011-10-28 2016-03-30 Regeneron Pharma Humanized il-6 and il-6 receptor
HUE048511T2 (hu) 2011-10-28 2020-07-28 Regeneron Pharma Kiméra fõ hisztokompatibilitási komplex (MHC) II molekulákat expresszáló, genetikailag módosított egerek
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
EP4193834A1 (fr) 2012-09-07 2023-06-14 Yale University Animaux non humains génétiquement modifiés et leurs procédés d'utilisation
EP3556206B1 (fr) 2012-11-05 2021-06-02 Regeneron Pharmaceuticals, Inc. Rongeurs génétiquement modifiés et leurs procédés d'utilisation
HUE045478T2 (hu) 2013-02-20 2019-12-30 Regeneron Pharma Humanizált T-sejt koreceptorokat expresszáló egerek
JP6444321B2 (ja) 2013-02-22 2018-12-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化主要組織適合性遺伝子複合体を発現するマウス
RS64573B1 (sr) 2013-09-23 2023-10-31 Regeneron Pharma Ne-humana životinja sa humanizovanim signalno-regulatornim proteinskim genom
CN107529739B (zh) * 2015-04-30 2021-01-08 株式会社特殊免疫研究所 表达人特定分子和人Fcγ受体家族的转基因非人动物

Also Published As

Publication number Publication date
US20170265442A1 (en) 2017-09-21
EP4269430A3 (fr) 2024-01-10
PH12016500342A1 (en) 2016-05-02
IL297607A (en) 2022-12-01
RU2016110462A3 (fr) 2018-03-30
EP3175706B1 (fr) 2018-11-07
HUE063376T2 (hu) 2024-01-28
DK2922394T3 (en) 2017-05-15
JP6453893B2 (ja) 2019-01-16
US9901083B2 (en) 2018-02-27
IL278679A (en) 2022-12-01
IL297607B2 (en) 2024-01-01
US9462794B2 (en) 2016-10-11
US10426146B2 (en) 2019-10-01
US20150089679A1 (en) 2015-03-26
US20190124895A1 (en) 2019-05-02
US9193977B2 (en) 2015-11-24
JP6665269B2 (ja) 2020-03-13
PL3434101T3 (pl) 2024-02-19
IL244187A0 (en) 2016-04-21
RU2016110462A (ru) 2017-10-30
EP3175706A1 (fr) 2017-06-07
KR102407354B1 (ko) 2022-06-10
US9127292B2 (en) 2015-09-08
SI3434101T1 (sl) 2023-11-30
NZ717817A (en) 2022-07-01
CN108441497B (zh) 2021-10-29
SG11201601184UA (en) 2016-03-30
ES2710282T3 (es) 2019-04-24
IL278679B2 (en) 2023-04-01
EP2922394B1 (fr) 2017-02-22
PT2922394T (pt) 2017-05-22
SG10201902547SA (en) 2019-04-29
DK3175706T3 (en) 2019-03-04
IL244187B (en) 2018-11-29
CN105592695A (zh) 2016-05-18
SG10201801326PA (en) 2018-03-28
US20180139941A1 (en) 2018-05-24
RU2018136614A (ru) 2018-11-27
AU2014321187B2 (en) 2020-09-17
SI3175706T1 (sl) 2019-03-29
US20210251201A1 (en) 2021-08-19
JP2020114209A (ja) 2020-07-30
HRP20231121T1 (hr) 2023-12-22
IL262958A (en) 2018-12-31
JP6875573B2 (ja) 2021-05-26
LT3434101T (lt) 2023-09-25
RU2671166C2 (ru) 2018-10-29
US20160374321A1 (en) 2016-12-29
AU2020286187A1 (en) 2021-01-07
TR201901782T4 (tr) 2019-03-21
RS64573B1 (sr) 2023-10-31
IL297607B1 (en) 2023-09-01
MX368931B (es) 2019-10-22
ES2959333T3 (es) 2024-02-23
LT3175706T (lt) 2019-02-25
EP3434101A1 (fr) 2019-01-30
US10206379B2 (en) 2019-02-19
JP7149370B2 (ja) 2022-10-06
US20200187468A1 (en) 2020-06-18
EP2922394A1 (fr) 2015-09-30
EP4269430A2 (fr) 2023-11-01
MX2016003636A (es) 2016-07-21
KR20220032125A (ko) 2022-03-15
CA2925564C (fr) 2023-03-21
HRP20190227T1 (hr) 2019-06-14
JP2019047818A (ja) 2019-03-28
US11019810B2 (en) 2021-06-01
US20150089678A1 (en) 2015-03-26
DK3434101T3 (da) 2023-10-02
WO2015042557A1 (fr) 2015-03-26
KR102370419B1 (ko) 2022-03-04
ES2624614T3 (es) 2017-07-17
CA2925564A1 (fr) 2015-03-26
PT3434101T (pt) 2023-09-19
HUE042412T2 (hu) 2019-06-28
JP2021104064A (ja) 2021-07-26
PL3175706T3 (pl) 2019-05-31
WO2015042557A4 (fr) 2015-06-18
CY1121410T1 (el) 2020-05-29
PT3175706T (pt) 2019-02-11
CN105592695B (zh) 2018-04-10
ZA201601138B (en) 2020-06-24
JP2016537015A (ja) 2016-12-01
US20160050896A1 (en) 2016-02-25
KR20160056900A (ko) 2016-05-20
CN108441497A (zh) 2018-08-24
FI3434101T3 (fi) 2023-10-02
EP3434101B1 (fr) 2023-08-16
US9700027B2 (en) 2017-07-11
RS58365B1 (sr) 2019-03-29

Similar Documents

Publication Publication Date Title
IL297607B1 (en) Non-human animals with a humanized signal-regulatory protein gene
IL269907B (en) Humanized animals for – il–15
HK1219961A1 (zh) 人抗α型干擾素抗體
EP2967010A4 (fr) Système de régulation d'ammoniac pour l'aquaculture
EP2868192A4 (fr) Litière pour animal
GB201308057D0 (en) Protein
PL3016977T3 (pl) Ludzkie przeciwciała anty-IL-32
GB201401955D0 (en) Protein
GB201302031D0 (en) Protein
GB201302030D0 (en) Protein
GB201309292D0 (en) Animal training aid
GB201302062D0 (en) Animal training aid